Jan Pencik received the Novartis Award of the German Society for Pathology for his research on prostate cancer, which was performed at the LBI-CR.
At the spring conference of the Austrian Society for Hematology and Medical Oncology (OeGHO) Barbara Maurer received a poster award in oncology for her research presented under the title "An Activating Mutation of STAT5 Drives Peripheral T Cell Lymphomas". Profs. Hellmut Samonig and Ulrich Jäger highlighted the outstanding work of many young researchers contributing to the conference. The entire institute congratulates Barbara to this very fine success.
The LBI-CR looks back onto an unusually successful year 2015, which has seen significant progress in organizational aspects, but it is also characterized by an outstanding scientific output in the form of publications and an increasing participation in international research projects. The new annual report of 2015 provides not only a comprehensive scientific overview, but also impressive data that in 2015 the institute surpassed previous years with respect to many output parameters.
In 2015 key researchers of the LBI-CR contributed to 40 publications in peer reviewed journals with a cumulative impact factor of 310. Of these publications eleven were led by key researchers from the LBI-CR and nine of these achieved an IF > 3.
The LBI has recently restructured to prepare for a budget cut by the LBG. For the research program to remain competitive and stable at a high level therefore researchers are increasingly reliant on third party funds. We are therefore proud to report not only that recently researchers obtained prestigious EU funded grants, but also that the contribution of third party funds to the annual budget is stable at a very high level of 600,000 €, which corresponds now to 24% of our total budget.
The FFG has now decided to fund a new project entitled "Identification of novel STAT3/5 inhibitors to interfere with the oncogenic activities of STATs in hematopoietic cancer" in collaboration of Prof. Richard Moriggl of the LBI-CR and Prof. Patrick Gunning of the University Toronto, which aims to identify new compounds blocking STAT function in cancer. STATs are hyper activated in many solid and hematopoietic cancers due to mutations in upstream kinases or point mutations in conserved domains of STAT proteins.